Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.
HIV-infected drug users have increased age-matched morbidity and mortality compared with HIV-infected people who do not use drugs. Substance-use disorders negatively affect the health of HIV-infected drug users, who also have frequent medical and psychiatric comorbidities that complicate HIV treatment and prevention. Evidence-based treatments are available for the management of substance-use disorders, mental illness, HIV and other infectious complications such as viral hepatitis and tuberculosis, and many non-HIV-associated comorbidities. Tuberculosis co-infection in HIV-infected drug users, including disease caused by drug-resistant strains, is acquired and transmitted as a consequence of inadequate prescription of antiretroviral therapy, poor adherence, and repeated interfaces with congregate settings such as prisons. Medication-assisted therapies provide the strongest evidence for HIV treatment and prevention efforts, yet are often not available where they are needed most. Antiretroviral therapy, when prescribed and adherence is at an optimum, improves health-related outcomes for HIV infection and many of its comorbidities, including tuberculosis, viral hepatitis, and renal and cardiovascular disease. Simultaneous clinical management of multiple comorbidities in HIV-infected drug users might result in complex pharmacokinetic drug interactions that must be adequately addressed. Moreover, interventions to improve adherence to treatment, including integration of health services delivery, are needed. Multifaceted, interdisciplinary approaches are urgently needed to achieve parity in health outcomes in HIV-infected drug users.
Altice
Frederick L
FL
Department of Medicine, Section of Infectious Diseases, Yale University, New Haven, CT 06510-2283, USA. frederick.altice@yale.edu
Kamarulzaman
Adeeba
A
Soriano
Vincent V
VV
Schechter
Mauro
M
Friedland
Gerald H
GH
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology; D015897:Comorbidity; D003416:Criminal Law; D004347:Drug Interactions; D024881:Drug Resistance, Bacterial; D019317:Evidence-Based Medicine; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000401:mortality; D006525:Hepatitis, Viral, Human / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D055118:Medication Adherence; D001523:Mental Disorders / Q000188:drug therapy* / Q000453:epidemiology; D009294:Narcotics / Q000008:administration & dosage / Q000627:therapeutic use*; D011329:Prisoners; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000453:epidemiology* / Q000401:mortality; D014376:Tuberculosis / Q000188:drug therapy
D019380:Anti-HIV Agents; D014150:Antipsychotic Agents; D000995:Antitubercular Agents; D000998:Antiviral Agents; D009294:Narcotics